| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-05 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.16 | 7e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.22 | 9e-05 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.2 | 0.0002 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.35 | 0.0003 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |